Amprolium hydrochloride veterinary-grade API is a white to off-white crystalline salt with a quaternary pyridinium heterocycle and a pyrimidine side chain. The molecule acts as a thiamine structural analogue and suppresses coccidial schizont development in target epithelia. Downstream manufacture is restricted to non-sterile oral presentations because amprolium HCl is not routinely formulated as a parenteral product in major regulatory markets. The following application sections address the formulation use levels, process controls, regulatory reference texts, and finished-product variants for poultry, ruminant, and compounding channels.

Two water-borne amprolium delivery modes dominate broiler barn protocols: a 20% w/w soluble powder for tank mixing and a 9.6% w/v oral concentrate for proportional medicators. In tank mixing, the target final drinking-water concentration is 0.012% for prevention and 0.024% for elevated challenge, with daily prepared volumes calculated from metered water intake per 1,000 birds rather than bird bodyweight alone. The dry powder is manufactured by preblending amprolium HCl with dextrose monohydrate at a 1:1 ratio in a 200 L tumble blender, then geometrically diluting to full batch size in a horizontal ribbon mixer with an agitator tip speed of 1.2 m/s. Finished powder is filled at residual moisture below 0.8% into low-moisture-barrier pouches; headspace oxygen is reduced to below 5.0% by nitrogen flush before sealing. Regulatory compliance for broiler feed and water products is derived from 21 CFR 558.55 for feed-grade use and the approved NADA label for water soluble powder; batch release includes assay by reversed-phase high-performance liquid chromatography with USP <621> system suitability and assay limits of 95.0–105.0% of label claim. Terminal finished types are 20% water-soluble powder, 9.6% oral liquid, and proportioner-ready concentrate in 1 kg pouches and 3.8 L jugs. Operational boundary: reconstituted amprolium solution should be consumed within 24 h; water with pH above 8.5 or carbonate hardness exceeding 300 mg/L may shorten chemical stability, and published stability data for alkaline well water are limited.

Can a 25% Type A Premix Maintain Content Uniformity Across Rotating Anticoccidial Programmes?

Amprolium HCl is used in replacement pullet feed as part of rotation and shuttle programmes intended to limit selection pressure on Eimeria tenella, E. acervulina, and E. necatrix populations. The Type A medicated article is manufactured at 25% w/w on a calcium carbonate or rice hull carrier, then diluted by feed mills to a Type B intermediate at 2.5% w/w and a final complete-feed level of 0.0125% or 0.025% according to stage. Higher final inclusion is generally reserved for clinical suppression in pullets before 16 weeks of age, while the lower inclusion is used in grower rations as a preventative step before transfer to an ionophore. Mixing is executed in a horizontal double-ribbon mixer with a coefficient of variation below 5% based on ISO 6497 sampling; dry blending for 6 min is followed by 1 min post-liquid addition mixing, with liquid soybean oil or mineral oil added at 0.5–1.0% w/w to suppress dust and segregation. The finished complete feed is assayed by near-infrared spectroscopy calibrated against a validated high-performance liquid chromatographic method; acceptance is set at 90–110% of labelled amprolium. Compliance documents include 21 CFR 558.55, feed hygiene requirements of ISO 22000, and regional veterinary-feed-directive or prescription requirements where applicable. Terminal product types are 25% Type A amprolium premix, 2.5% Type B intermediate, and complete grower, developer, or pullet mashes, crumbles, and pellets. Operational boundary: amprolium should not be placed in feed for hens producing eggs for human food unless the national label expressly permits it; simultaneous use with thiamine-supplemented vitamin packs at the same mix step may reduce analytical recovery if sampling is delayed.

Oral Drench and Tablet Workability in Neonatal Ruminants: pH, Dosing Accuracy, and Regional Stability

For calf coccidiosis caused by Eimeria zuernii and Eimeria bovis, amprolium HCl is formulated as a 9.6% w/v oral drench in purified water adjusted to pH 3.0–4.5 with citric acid and sodium citrate. The US reference 21 CFR 520.100 governs oral solution use in cattle, and manufacturing is conducted under non-sterile veterinary GMP with in-line 5 µm polypropylene depth filtration before filling into high-density polyethylene drench bottles or 3.8 L jugs. Dosing chambers of 30 mL are calibrated to ±0.5 mL and labelled according to bodyweight brackets; label schedules commonly cite 10 mg/kg bodyweight once daily for 5 days for treatment, with veterinary verification required because regional product inserts differ. Direct-compression tablets containing 150 mg amprolium HCl are produced on a 16-station rotary tablet press equipped with B tooling; microcrystalline cellulose is used as the compression aid, crospovidone as the disintegrant at 2.0% w/w, and magnesium stearate as lubricant at 0.5% w/w. Tablet hardness is maintained at 45–70 N, and friability is controlled below 1.0% per USP <1216>, while content uniformity follows USP <905> with acceptance value below 15.0. Terminal finished types are 9.6% oral drench, 150 mg direct-compression tablets, and calibrated 30 mL dosing chamber packs. Operational boundary: tablet use should not be assumed bioequivalent to oral solution in pre-ruminating calves; published comparative bioavailability data for this specific tablet configuration is limited, and acidification of drinking water at the same time may shift feed intake in milk-fed calves.

Ovine and caprine oral dosing equipment imposes suspension viscosity and syringeability limits that differ from cattle drench lines. Amprolium HCl is dispersed into a molasses-based or purified-water vehicle at 9.6% w/v for concentrated drench, then diluted to 0.5% ready-to-use suspension for lambing shed administration. Xanthan gum at 0.3% w/w is hydrated under high shear at 12,000 rpm for 15 min to achieve a yield stress below 5 Pa, preventing sedimentation of fine API particles in 20 mL auto-fill drench guns. A second viscosity-control option uses 0.5% w/w microcrystalline cellulose co-processed with sodium carboxymethylcellulose for a thixotropic carrier that does not obstruct the check valve of automatic syringes. The label treatment regimen in many sheep and goat jurisdictions is 20 mg/kg once daily for 5 days; however published pharmacokinetic data for this species-specific configuration are limited, and regional product inserts must take precedence over any externally stated schedule. Regulatory compliance for compounded oral suspensions follows USP <795> in the United States and equivalent regional extemporaneous preparation chapters; residual solvent assessment is aligned with VICH GL18(R2). Cross-contamination control is a production bottleneck: separate granulation rooms or validated wash cycles are required after thiamine hydrochloride premixes because amprolium is a thiamine analogue and carryover of either entity creates an antagonism risk in multivitamin feeds. Terminal product types are 9.6% oral drench concentrate, 0.5% ready-to-use suspension, 20 L backpack reservoirs, and 1 L dosing gun bottles. Operational boundary: do not process amprolium suspensions in laminar-flow suites used for injectable vitamins; the aqueous film left on transfer lines can create a thiamine-antagonist residue not detected by standard visual cleaning.

When Capsule and Granule Unit Operations Are Used for Compounded Veterinary Delivery

Compounded capsule production of amprolium HCl typically begins with top-spray fluid-bed granulation of a 25% w/w active blend with pregelatinized maize starch and copovidone binder. Inlet air temperature is held at 45–65°C, product temperature at 30–38°C, and binder spray rate at 8–15 g/min/kg; final granule moisture is dried to ≤ 2.0% by USP <731>. The dried granule is blended with colloidal silicon dioxide at 0.5% w/w in a low-shear bin blender for 10 min and encapsulated into size 3 or size 4 hard gelatin capsules on semi-automatic equipment running at 12,000 capsules/h; fill weight variability is held at ±5%. A 100 mg dose in a size 4 capsule is achievable at this granule strength, while 200 mg doses require size 3 capsules or dual-capsule administration. Non-sterile compounding in the United States falls under USP <795>, and residual solvent testing is aligned to ICH Q3C(R8) and VICH GL18(R2). Terminal finished types are 25% amprolium granule blends, 100 mg and 200 mg hard gelatin capsules, and single-dose granule sachets for zoo or companion animal use. Operational boundary: amprolium HCl should not be compounded into injectable or ophthalmic preparations unless a stability-indicating method and terminal sterilization compatibility study are available; published data on parenteral amprolium formulation are limited, and preparation of an injectable dosage form should not be attempted without empirical validation of pH, antioxidant content, and terminal sterilization effects on the pyrimidine ring.

Turkey poult floor-pen units require a different water-mediation calculation than broiler barns because poults consume more water per unit bodyweight during the first 14 days and are susceptible to Eimeria meleagrimitis, Eimeria adenoeides, and Eimeria gallopavonis. Amprolium HCl soluble powder is metered through a proportional medicator at a stock concentration that delivers 0.012% to 0.024% in the drinking water, with the lower concentration used in low-challenge grow-out and the higher in diagnosed outbreaks. The medicator stock is prepared by mixing 20% powder with water to a stock concentration calculated as final target multiplied by pump ratio; for a 1:128 pump and 0.024% final water, stock concentration is 3.1%. Pump calibration against actual flow is required because diaphragm medicators lose accuracy at flow rates below 5 L/min. The finished powder is manufactured under dry blending conditions with residual moisture below 0.8% and filled into aluminium-foil-lined pouches to prevent clumping in humid brooder houses. Regulatory recognition for turkey feed is included in 21 CFR 558.55 at 0.0125% to 0.025%; water use must follow the applicable approved label or prescribing cascade in countries that apply veterinary prescription control. Terminal product types are 20% soluble powder, 9.6% oral liquid, and proportional medicator stock solutions in 5 L low-density polyethylene canisters. Operational boundary: poult water intake may drop during Eimeria infection; if the medicated water is not consumed, feed-based intervention may be required, and published field data comparing water and feed routes in turkey poults are limited.